chikungunya
viru
chikv
emerg
one
signific
arbovir
threat
mani
part
world
spite
larg
scale
morbid
long
last
polyarthralgia
licens
vaccin
antivir
avail
clinic
manag
chikv
infect
studi
novel
rna
interfer
base
strategi
adopt
effect
inhibit
chikv
four
artifici
microrna
amirna
design
target
differ
region
chikv
genom
amirna
significantli
inhibit
chikv
replic
vero
cell
rna
protein
level
assess
qrtpcr
immunoblot
immunofluoresc
techniqu
inhibit
infecti
chikv
demonstr
plaqu
reduct
assay
concatemer
amirna
result
higher
inhibit
chikv
individu
amirna
addit
studi
effect
combin
rnai
base
therapi
classic
antivir
like
chloroquin
ribavirin
mycophenol
acid
help
understand
ration
select
rnai
base
combin
therapi
find
provid
promis
avenu
develop
novel
amirna
combin
base
therapeut
emerg
chikv
chikungunya
viru
chikv
emerg
major
threat
public
health
recent
year
chikv
member
genu
alphaviru
famili
togavirida
first
isol
tanzania
thibervil
et
al
chikv
recogn
global
arbovir
threat
numer
major
outbreak
report
old
new
world
sinc
power
chikv
infect
human
character
acut
chronic
form
ill
acut
chikv
infect
characteris
abrupt
onset
fever
headach
fatigu
nausea
vomit
rash
myalgia
sever
arthralgia
acutephas
symptom
usual
disappear
week
howev
arthralgia
andor
myalgia
may
persist
week
month
even
year
patient
persist
chikv
joint
may
characterist
chronic
ill
simon
et
al
labadi
et
al
dupuismaguiraga
et
al
sever
complic
includ
neurolog
involv
mothertochild
transmiss
even
death
report
recent
outbreak
chandak
et
al
gerardin
et
al
despit
occurr
numer
outbreak
across
world
approv
vaccin
therapeut
current
avail
mani
antivir
molecul
report
inhibit
chikv
includ
arbidol
chloroquin
favipiravir
furin
inhibitor
monoclon
antibodi
interferona
mycophenol
acid
synthas
ribavirin
etc
success
howev
fulli
translat
clinic
applic
multipl
strategi
involv
tissu
cultur
anim
model
appli
gener
novel
therapi
chikv
abdelnabi
et
al
contribut
acceler
surg
drug
discoveri
chikv
explor
novel
rna
interfer
rnai
strategi
inhibit
replic
chikv
rna
interfer
rnai
therapeut
recent
emerg
new
field
drug
discoveri
numer
studi
involv
rnai
publish
sever
rnai
drug
candid
enter
clinic
trial
burnett
et
al
davidson
mccray
pecot
et
al
last
decad
wit
major
advanc
rnai
base
antivir
therapeut
approach
demonstr
efficaci
acut
chronic
viral
infect
includ
ebola
viru
influenza
viru
sever
acut
respiratori
syndrom
sar
west
nile
viru
japanes
enceph
viru
hepat
c
viru
hepat
b
viru
etc
thi
et
al
tompkin
et
al
ge
et
al
li
et
al
haasnoot
et
al
rnai
therapeut
primarili
achiev
util
exogen
sirna
vectorbas
shrna
mirna
approach
rnai
target
chikv
use
sirna
shrna
alreadi
report
dash
et
al
parashar
et
al
lam
et
al
artifici
mirna
amirna
base
approach
gain
import
owe
advantag
sirna
shrna
term
increas
stabil
effect
lower
toxic
boudreau
et
al
maczuga
et
al
mcbride
et
al
xie
et
al
like
natur
endogen
mirna
amirna
express
exogen
transfect
plasmid
mirna
construct
rna
polymeras
ii
primari
microrna
primirna
transcrib
trim
microprocessor
complex
made
drosha
rnase
iii
nucleu
nucleotid
stemloop
precursor
call
premirna
follow
preamirna
transport
cytoplasm
via
recogn
rnainduc
silenc
complex
risc
preamirna
cleav
matur
amirna
dicer
two
strand
amirna
separ
guid
strand
complementari
viral
gene
remain
associ
orient
interact
target
viral
rna
carthew
sontheim
davidson
mccray
fischer
jame
kim
rossi
van
rij
andino
target
viral
rna
subsequ
degrad
translat
inhibit
result
posttranscript
silenc
viral
replic
recent
effect
amirna
report
inhibit
venezuelan
equin
enceph
viru
veev
member
genu
alphaviru
bhomia
et
al
studi
design
clone
four
amirna
commerci
avail
mirna
express
vector
target
chikv
amirna
plasmid
construct
transfect
vero
cell
infect
chikv
result
reveal
amirna
either
singl
combin
differ
target
effici
inhibit
chikv
replic
grow
studi
suggest
combinatori
therapi
hold
signific
promis
monotherapi
help
maxim
efficaci
minim
risk
escap
mutant
therefor
blend
amirna
base
rnai
approach
classic
inhibitor
chikv
work
provid
inform
ration
select
effici
regim
effect
suppress
chikv
vero
cell
african
green
monkey
kidney
cell
line
obtain
nation
center
cell
scienc
ncc
pune
india
cultur
minimum
essenti
medium
mem
supplement
fetal
bovin
serum
fb
u
gentamicin
mm
lglutamin
gl
sodium
bicarbon
indian
isol
chikv
strain
genbank
acc
belong
east
central
south
african
ecsa
genotyp
maintain
virolog
divis
drde
gwalior
use
present
studi
viru
propag
use
standard
viru
adsorpt
techniqu
titrat
plaqu
assay
vero
cell
aliquot
store
c
till
use
four
amirna
target
conserv
region
nonstructur
structur
orf
chikv
design
use
web
base
blockit
rnai
design
tool
invitrogen
usa
sequenc
oligo
along
genom
posit
inhibit
gene
orf
shown
tabl
amirna
target
nonspecificscrambl
sequenc
also
use
neg
control
studi
top
bottom
strand
oligo
custom
synthes
hplc
grade
anneal
clone
vector
invitrogen
usa
cytomegaloviru
promot
driven
express
construct
cocistron
express
emerald
green
fluoresc
protein
emgfp
amirna
constitut
posit
construct
confirm
doubl
pass
nucleotid
sequenc
use
vector
specif
primer
construct
design
amirnaa
amirnab
amirnac
amirnad
determin
cellular
toxic
amirna
vero
cell
seed
plate
confluenc
differ
concentr
amirna
rang
transfect
use
lipofectamin
invitrogen
usa
replic
per
concentr
cell
control
mock
transfect
control
kept
along
side
follow
transfect
medium
replenish
mem
supplement
fb
cell
incub
h
cytotox
analyz
neutral
red
dye
uptak
nrdu
assay
repetto
et
al
vero
cell
seed
plate
confluenc
cell
wash
transient
transfect
mg
well
amirna
plate
incub
h
transfect
reagent
replenish
mem
supplement
fb
follow
h
post
transfect
cell
infect
chikv
multipl
infect
moi
h
adsorpt
plate
wash
replenish
mem
fb
mock
transfect
control
viru
control
scrambl
amirna
kept
alongsid
infect
cultur
supernat
harvest
h
post
infect
hpi
viral
rna
isol
infect
cultur
supernat
hpi
use
qiaamp
viral
rna
kit
qiagen
germani
quantit
rtpcr
qrtpcr
assay
use
quantifi
chikv
rna
copi
describ
previous
agarw
et
al
briefli
qrtpcr
carri
use
ss
iii
platinum
one
step
qrtpcr
kit
invitrogen
usa
system
stratagen
usa
qrtpcr
reaction
perform
ml
reaction
volum
master
mix
gene
specif
forward
revers
primer
enzym
mix
compris
taq
dna
polymeras
revers
transcriptas
nucleas
free
water
rna
templat
cycl
paramet
revers
transcript
c
min
initi
denatur
c
min
follow
cycl
amplif
c
c
c
amplifi
product
verifi
melt
curv
analysi
use
softwar
titer
infecti
chikv
amirna
treatment
determin
use
plaqu
reduct
assay
vero
cell
seed
plate
one
day
prior
experi
serial
dilut
harvest
supernat
experiment
group
viru
control
amirnanc
differ
amirna
treatment
group
prepar
ml
dilut
ad
respect
well
follow
viru
adsorpt
overlay
medium
contain
carboxymethyl
cellulos
ad
plate
incub
h
plate
wash
fix
chill
methanol
final
stain
crystal
violet
solut
number
plaqu
count
titer
calcul
consid
volum
dilut
factor
inoculum
cell
cultur
condit
amirna
treatment
viru
infect
describ
hpi
cell
fix
chill
methanol
permeabil
cell
incub
antichikv
monoclon
antibodi
mab
follow
immunostain
fitc
conjug
antimous
antibodi
sigma
usa
final
cell
mount
fluoroshield
dapi
sigma
usa
imag
captur
use
fluoresc
microscop
leica
germani
vero
cell
transfect
infect
chikv
describ
cell
harvest
appear
cytopath
effect
cpe
viru
control
lyse
radioimmunoprecipit
assay
ripa
buffer
sigma
usa
contain
proteas
inhibitor
cocktail
sigma
usa
protein
quantifi
resolv
sdspage
follow
electroblot
onto
pvdf
membran
membran
block
probe
antichikv
mab
bactin
antibodi
follow
addit
antimous
horseradish
peroxidas
conjug
secondari
antibodi
antichikv
mab
use
detect
viral
protein
wherea
bactin
antibodi
serv
intern
protein
refer
load
control
combin
two
amirna
singl
vector
construct
carri
per
manufactur
protocol
blockit
kit
invitrogen
usa
briefli
gener
construct
express
two
amirna
first
amirna
segment
donor
plasmid
excis
restrict
enzym
bamhi
xhoi
ligat
anoth
amirna
backbon
vector
precut
bglii
xhoi
two
vector
construct
amirnabd
amirnacd
gener
combin
effect
concaten
amirna
inhibit
chikv
infect
vero
cell
assess
qrtpcr
plaqu
reduct
assay
immunoblot
techniqu
describ
maximum
nontox
dose
mntd
antivir
compound
ie
ribavirin
riba
mycophenol
acid
mpa
chloroquin
chlo
determin
vero
cell
use
nrdu
assay
experi
compound
carri
use
lower
dose
compar
respect
mntd
monolay
vero
cell
seed
plate
cell
transfect
mg
amirnad
respect
well
h
prior
infect
follow
overnight
transfect
plate
infect
chikv
moi
h
adsorpt
antivir
compound
mm
chlo
riba
mm
mpa
mem
supplement
fb
ad
respect
well
triplic
plate
incub
c
co
result
analyz
base
appear
cytopath
effect
cpe
infect
cultur
supernat
harvest
hpi
analysi
qrtpcr
assay
perform
three
time
sampl
triplic
result
graph
error
bar
indic
mean
standard
deviat
sd
data
analyz
use
two
tail
student
ttest
oneway
anova
posthoc
tukey
hsd
test
asterisk
indic
statist
signific
pvalu
pvalu
pvalu
amirna
oligonucleotid
clone
vector
recommend
manufactur
protocol
result
four
chikv
specif
amirna
express
plasmid
amirnaa
amirnab
amirnac
amirnad
neg
control
mirna
express
plasmid
amirnanc
posit
recombin
plasmid
confirm
nucleotid
sequenc
data
shown
order
test
toxic
amirna
vero
cell
well
plate
transfect
differ
concentr
amirna
ng
per
well
assess
nrdu
cell
viabil
assay
h
post
transfect
effect
viabil
vero
cell
observ
ng
concentr
viabil
ng
amirna
concentr
viabil
observ
fig
b
transfect
h
typic
fluorescenceposit
cell
observ
fig
show
transient
transfect
emgfpamirna
construct
suitabl
indic
test
transfect
effici
efficaci
amirna
evalu
transfect
mg
plasmid
vero
cell
h
prior
infect
chikv
rna
collect
infect
cell
supernat
hpi
qrtpcr
plaqu
reduct
analysi
compar
infect
vero
cell
cell
express
amirnaa
amirnab
amirnac
amirnad
exhibit
mark
reduct
chikv
rna
measur
qrtpcr
hpi
qrtpcr
analysi
show
rna
load
viru
control
log
log
hpi
respect
chikv
rna
amirnaa
amirnab
amirnac
amirnad
treat
cell
respect
hpi
similarli
hpi
viral
rna
transcript
log
log
log
log
amirnaa
amirnab
amirnac
amirnad
respect
rel
express
chikv
rna
shown
fig
highest
reduct
chikv
rna
observ
amirnad
treat
cell
follow
amirnab
amirnac
amirnaa
rel
titer
infecti
chikv
depict
fig
chikv
titer
amirnaa
amirnab
amirnac
amirnad
treat
cell
pfuml
respect
hpi
compar
pfuml
viru
control
amirnanc
respect
analysi
indirect
immunofluoresc
assay
reveal
reduct
chikv
load
amirna
transfect
group
compar
control
notabl
fluoresc
bare
detect
cell
treat
amirnad
follow
amirnab
compar
viru
control
amirnanc
hpi
fig
downregul
protein
also
assess
western
blot
faint
band
protein
kda
observ
amirnad
transfect
cell
follow
amirnab
compar
viru
control
amirnanc
protein
band
observ
mock
cell
control
cell
express
bactin
protein
equival
level
nevertheless
ad
scrambl
amirna
amirnanc
construct
affect
viral
replic
fig
b
combin
two
best
amirna
amirnabd
result
signific
inhibit
replic
chikv
assess
qrtpcr
immunofluoresc
plaqu
assay
immunoblot
techniqu
fig
overal
inhibit
amirnabd
higher
amirnab
amirnad
alon
howev
effect
amirnacd
found
margin
compar
amirnac
amirnad
next
investig
inhibitori
effect
amirnad
combin
classic
antivir
drug
like
riba
mpa
chlo
chlo
treatment
amirnad
transfect
vero
cell
reveal
mark
reduct
viral
load
shown
reduc
cpe
comparison
amirnad
chloroquin
alon
howev
cell
transfect
neg
control
plasmid
amirnanc
show
extens
cpe
within
h
infect
combin
effect
seen
riba
mpa
treat
amirnad
transfect
cell
contrari
effect
combin
treatment
less
inhibitori
effect
amirnad
ribampa
alon
fig
mpa
data
shown
similar
riba
addit
examin
cpe
replic
chikv
viral
rna
load
studi
viral
genom
copi
number
amirnad
riba
mpa
chlo
log
log
log
log
log
log
log
hpi
log
log
log
log
log
log
log
copi
hpi
respect
contrast
viru
control
reveal
chikv
rna
titer
log
log
copi
hpi
hpi
respect
rel
express
chikv
rna
respect
viru
control
shown
fig
rnai
therapeut
attempt
variou
genera
virus
recent
past
expans
chikv
across
differ
contin
attract
attent
research
toward
develop
effect
therapeut
inhibitori
effect
sirna
shrna
alreadi
demonstr
chikv
howev
report
avail
regard
inhibit
chikv
vectordeliv
amirna
though
mirna
believ
potenti
sirna
shrna
control
express
amirna
rna
polymeras
ii
result
lower
cytotox
due
rel
low
concentr
insid
cell
lead
better
rnai
respons
shrna
sirna
boudreau
et
al
maczuga
et
al
xie
et
al
present
studi
evalu
effect
vectordeliv
mirna
chikv
replic
vero
cell
result
show
mirna
base
rnai
could
effici
inhibit
chikv
replic
irrespect
target
orfgen
ultim
result
either
translat
repress
cleavag
entir
rna
transcript
one
import
advantag
mirnabas
express
vector
system
abil
express
multipl
amirna
singl
construct
possibl
regular
shrna
vector
construct
concaten
amirna
express
vector
allow
simultan
express
differ
amirna
combin
two
amirna
differ
genom
target
chikv
result
statist
signific
improv
inhibitori
effect
compar
individu
amirna
previous
report
express
one
amirna
singl
construct
result
better
inhibit
rabi
viru
replic
israsena
et
al
combin
system
also
effect
util
antihiv
studi
prevent
gener
escap
mutant
persist
hiv
infect
haasnoot
et
al
zhang
et
al
success
rnai
base
therapeut
suggest
suppress
viral
replic
effici
ibrisimov
et
al
jacqu
et
al
van
rij
andino
howev
apprehens
amirna
base
rnai
may
face
obstacl
seen
monotherapi
past
lead
develop
resist
address
concern
studi
extend
evalu
inhibitori
effect
amirna
combin
convent
antivir
drug
like
chloroquin
ribavirin
chikv
infect
inhibitori
effect
chloroquineamirna
combin
found
much
greater
individu
compound
could
due
fact
combin
two
compound
led
target
viru
life
cycl
earli
late
stage
chloroquin
amirna
respect
chloroquin
interfer
fusion
viral
protein
endosom
membran
rais
endosom
ph
wherea
amirna
act
posttranscript
silenc
viral
replic
earlier
ribavirin
combin
infa
doxycyclin
reveal
synergist
inhibitori
effect
chikv
briolant
et
al
rothan
et
al
howev
studi
ribavirinamirna
combin
exhibit
desir
effect
compar
ribavirin
amirna
major
mechan
ribavirin
inhibit
inosin
monophosph
dehydrogenas
enzym
impdh
result
deplet
intracellular
gtp
pool
khan
et
al
abdelnabi
et
al
thu
ribavirin
might
interfer
mirna
pathway
well
also
requir
cellular
nucleotid
pool
express
nevertheless
test
possibl
use
anoth
nucleotid
analogu
mycophenol
acid
found
similar
result
collect
result
indic
use
inhibitor
viral
genom
replic
combin
amirna
may
interfer
express
amirna
result
ineffect
suppress
viral
replic
howev
combin
amirna
base
rnai
approach
suitabl
earli
viral
replic
inhibitor
significantli
help
suppress
viral
replic
fig
far
amirna
test
vivo
acut
viral
infect
howev
rnai
recent
use
inhibit
lethal
infect
ebola
viru
variou
anim
model
intraven
deliveri
protect
anim
death
includ
receiv
treatment
even
onset
ebola
infect
thi
et
al
studi
use
lipofectamin
base
protocol
vitro
transfect
nevertheless
lipidbas
deliveri
rnai
yield
success
advanc
vivo
extent
clinic
trial
bobbin
rossi
dong
et
al
torrecilla
et
al
wittrup
lieberman
moreov
rnai
therapeut
tkmebola
also
success
use
ebola
epidem
western
africa
bobbin
rossi
report
confirm
potenti
util
rnai
acut
viral
infect
plasmid
dna
vector
gene
therapi
success
employ
arthriti
model
use
variou
physic
chemic
method
deliveri
plasmid
dna
arthriti
gene
therapi
show
promis
therapeut
strategi
may
explor
system
deliveri
amirna
particularli
chronic
phase
chikv
infect
human
evan
et
al
subang
gould
first
report
success
appli
vectordeliv
mirna
inhibit
replic
chikv
effici
vitro
inhibit
chikv
replic
amirna
make
promis
candid
develop
antichikv
therapeut
target
conserv
sequenc
across
genotyp
chikv
make
excel
candid
combinatori
rnai
give
insight
ration
select
combin
regim
futur
howev
efficaci
amirna
remain
test
vivo
although
knowledg
rnai
therapeut
combin
therapi
increas
recent
year
sever
import
issu
must
studi
care
like
safe
deliveri
method
immun
respons
dose
combin
etc
knowledg
extend
develop
antichikv
therapeut
